Researchers are continuously investigating different mechanisms and pathways implicated in PAH to identify potential drug targets. For instance, research has highlighted the role of the prostacyclin pathway in PAH, leading to the development of prostacyclin analogs and receptor agonists. These drugs have demonstrated remarkable efficacy in improving exercise capacity, hemodynamics, and survival in PAH patients.
Advancements in drug delivery systems have also contributed to the field of Pulmonary Arterial Hypertension Drug research. The development of long-acting formulations and novel drug delivery methods has improved treatment convenience and compliance for patients. Inhaled therapies, such as inhaled prostacyclin analogs or endothelin receptor antagonists, provide targeted drug delivery to the lungs, minimizing systemic side effects. Similarly, implantable devices, like subcutaneous or intravenous infusion pumps, enable continuous administration of medications, reducing the burden of frequent dosing.
Discover More- http://latestcmiblogs.weebly.com/article/pulmonary-arterial-hypertension-drug-decreases-the-muscles-in-walls-of-blood-vessels
